Molecular analysis of peritoneal fluid in ovarian cancer patients

Modern Pathology

Volumn 16, Issue 7, 2003, Pages 636-640

  Parrella, Paola ^a,b   Zangen, Rachel ^a   Sidransky, David ^a   Nicol, Theresa ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Cytology; K ras; Microsatellite; Molecular detection; Ovarian cancer; p53; Peritoneal fluid

Indexed keywords

K RAS PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; ASCITES FLUID; CANCER CELL; CANCER DIAGNOSIS; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 22Q; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; OVARY TUMOR; PERITONEAL FLUID; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADENOCARCINOMA; ASCITIC FLUID; BASE PAIR MISMATCH; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 22; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; GENES, RAS; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MICRODISSECTION; MICROSATELLITE REPEATS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 0038107634     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000076979.28106.ED     Document Type: Article

References (27)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999;48:8-31.
2. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis and mortality. Cancer 1993;71:517-23.
3. Creasman WT, Rutlege F. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol 1971;110:773-8.
4. Tobias JS, Griffiths CT. Management of ovarian carcinoma. N Engl J Med 1976;294:818-23.
5. Motherby H, Nadjari B, Friegel P, Kohaus J, Ramp U, Bocking A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999;20:350-7.
6. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998;4:2433-7.
7. Quezado MM, Moskaluk CA, Bryant B, Mills SE, Merino MJ. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. Hum Pathol 1999;30:203-7.
8. Foster KA, Harrington P, Kerr J, Russel P, DiCioccio RA, Scott IV, et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 1996;1996:56:3622-5.
9. Cliby W, Ritland S, Hartmann L, Dodson M, Keeney G, Podratz KC, et al. Human epithelial ovarian cancer allelotype. Cancer Res 1993;53:2393-8.
10. Teneriello MG, Ebina M, Linoilla I, Henry M, Nash JD, Park RC, et al. P53 and K-ras mutations in epithelial ovarian neoplasm. Cancer Res 1993;53:3103-8.
11. Cutrecasas M, Villanueva A, Matia-Guiu X, Prat J. K-ras mutation in mucinous ovarian tumors: a clinicopathological study of 95 cases. Cancer 1997;79:1581-6.
12. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-9.
13. Milner JJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF. P53 mutation is a common genetic event in ovarian cancer. Cancer Res 1993;53:2128-2.
14. Kupryjanczyk J, Thor AD, Beuchamp R, Merrit V, Edgerton SM, Bell DA, et al. P53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90:4961-5.
15. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology 1998;12:399-406.
16. Narod SA, Boyd J. Current understanding of epidemiology and clinical implication of BRCA1 and BRCA2 mutation in ovarian cancer. Curr Opin Obstet Gynecol 2002;14:19-26.
17. Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, et al. Detection of mitochondrial DNA mutations in primary breast cancer and fine needle aspirates. Cancer Res 2001;61:7623-6.
18. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-62.
19. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997;3:621-4.
20. Hibi K, Robinson CR, Booke S, Wu L, Hamilt SR, Sidransky D, et al. Molecular detection of genetic alteration in the serum of colorectal cancer patients. Cancer Res 1998;58:1405-7.
21. Jen J, Powell SM, Papadopolous N, Smith KJ, Hamilto SR, Vogelstain B, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994;51:5523-6.
22. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
23. Hickey KP, Boyle KP, Jepps HM, Andrew AC, Buxton EJ, Burns PA. Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer 1999;80:1803-8.
24. Pieretti M, Powell DDE, Gallion HH, Case EA, Conway PS, Turker MS. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 1995;26:393-7.
25. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Parat J. K-ras mutation in non-mucinous ovarian tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer 1998;82:1088-95.
26. Fliss MS, Usadel H, Caballero O, Wu L, Buta M, Eleff M, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluid. Science (Wash DC) 2000;287:2017-9.
27. Ahrendt SA, Jow JT, Xu LH, Yang SC, Eisenberg CF, Esteller M, et al. Molecular detection of tumor cell in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-9.